351335-29-0

Basic information

• Product Name: 4-(2-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER
• Synonyms: 4-(2-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER;AKOS BBR-000700;BENZOIC ACID, 4-[(2-FORMYLPHENOXY)METHYL]-, METHYL ESTER
• CAS NO: 351335-29-0
• Molecular Formula: C₁₆H₁₄O₄
• Molecular Weight: 270.28
• Mol File: 351335-29-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 4-(2-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER(351335-29-0)
• EPA Substance Registry System: 4-(2-FORMYL-PHENOXYMETHYL)-BENZOIC ACID METHYL ESTER(351335-29-0)

Safety Data

• Hazardous Substances Data: 351335-29-0(Hazardous Substances Data)

Usage

Uses

Methyl 4-(2-Formylphenoxymethyl)benzoate

Upstream product

• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 90-02-8 salicylaldehyde 
• 6232-88-8 4-bromomethylbenzoic Acid 
• 34040-64-7 p-methyloxycarbonylbenzyl chloride 
• 1642-81-5 p-(chloromethyl)benzoic acid 

Downstream Products

• 1335113-30-8 C₃₄H₄₃N₃O₅ 

Relevant articles and documents

A potent leukocyte transmigration blocker: Gt-73 showed a protective effect against lps-induced ards in mice

We recently developed a molecule (GT-73) that blocked leukocyte transendothelial migration from blood to the peripheral tissues, supposedly by affecting the platelet endothelial cell adhesion molecule (PECAM-1) function. GT-73 was tested in an LPS-induced acute respiratory distress syndrome (ARDS) mouse model. The rationale for this is based on the finding that the mortality of COVID-19 patients is partly caused by ARDS induced by a massive migration of leukocytes to the lungs. In addition, the role of tert-butyl and methyl ester moieties in the biological effect of GT-73 was investigated. A human leukocyte, transendothelial migration assay was applied to validate the blocking effect of GT-73 derivatives. Finally, a mouse model of LPS-induced ARDS was used to evaluate the histological and biochemical effects of GT-73. The obtained results showed that GT-73 has a unique structure that is responsible for its biological activity; two of its chemical moieties (tert-butyl and a methyl ester) are critical for this effect. GT-73 is a prodrug, and its lipophilic tail covalently binds to PECAM-1 via Lys536. GT-73 significantly decreased the number of infiltrating leukocytes in the lungs and reduced the inflammation level. Finally, GT-73 reduced the levels of IL-1β, IL-6, and MCP-1 in bronchoalveolar lavage fluid (BALF). In summary, we concluded that GT-73, a blocker of white blood cell transendothelial migration, has a favorable profile as a drug candidate for the treatment of ARDS in COVID-19 patients.

BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION

The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.